Aspen Park Pharmaceuticals Overview
- Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
2
- Latest Deal Type
-
M&A
Aspen Park Pharmaceuticals General Information
Description
Developer of novel therapies for premature ejaculation in men. The company focuses on the development and commercialization of novel therapies for men's health diseases and conditions, including male secondary hypogonadism, prostate cancer, and sexual dysfunction.
Contact Information
Website
www.aspenparkpharma.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Office
- 944 Park Avenue
- New York, NY 10028
- United States
Aspen Park Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 31-Oct-2016 | 00.000 | Completed | Generating Revenue | ||
| 2. Seed Round | 31-Mar-2016 | 00.000 | 00.000 | Completed | Startup | |
| 1. Early Stage VC (Series A) | 10-Dec-2014 | Completed | Startup |
Aspen Park Pharmaceuticals Patents
Aspen Park Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190133977-A1 | Delayed release oral tamsulosin hydrochloride | Inactive | 04-May-2016 | 000000000 | |
| CA-3023106-A1 | Delayed release oral tamsulosin hydrochloride | Pending | 04-May-2016 | 000000000 | |
| EP-3452016-A1 | Delayed release oral tamsulosin hydrochloride | Inactive | 04-May-2016 | 000000000 | |
| AU-2017260505-A1 | Delayed release oral tamsulosin hydrochloride | Inactive | 04-May-2016 | 0000000000 | |
| AU-2017222567-A1 | Oral dosage form of both clomiphene isomers and method of using same to treat secondary hypogonadism | Inactive | 25-Feb-2016 | A61K31/138 |
Aspen Park Pharmaceuticals Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Harry Fisch MD | Co-Founder, Chairman & Chief Scientific Officer | ||
| Mitchell Steiner Ph.D | Co-Founder, President, Managing Director & Chief Executive Officer |
Aspen Park Pharmaceuticals Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Elgar Peerschke | Self | Board Member | 000 0000 |
| Sanjeev Dheer | Self | Board Member | 000 0000 |
Aspen Park Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
